Zelnorm: Not yet dead

It may make a comeback in a limited population:

Tegaserod (Zelnorm), the irritable bowel syndrome and constipation drug pulled from the market last spring, will make a limited return under an FDA plan that permits its use in certain symptomatic women younger than 55.

The FDA said today it will permit use of the drug under an investigational new drug (IND) protocol to treat IBS with predominant constipation and chronic idiopathic constipation in women in “critical need” whose physicians “decide the drug is medically necessary.”

Related posts:

1. Zelnorm, RIP
2. Fallout from the Zelnorm recall
3. Disease mongering chronic constipation
4. The patient-hitting cardiologist
5. Chronic disease management
6. Medicare drug negotiation
7. Why primary care doctors shouldn’t be pain specialists

  Follow on Twitter   Subscribe